NCT01772316View on ClinicalTrials.gov

A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

tocilizumab

162 mg subcutaneously weekly or every two weeks, 96 weeks

Trial Locations (12)

15006

A Coruña

15706

Santiago de Compostela

28007

Madrid

28046

Madrid

29009

Málaga

38320

San Cristóbal de La Laguna

39008

Santander

41009

Seville

46009

Valenica

48013

Bilbao

48903

Barakaldo

06800

Mérida

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01772316 - A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter